Modeling and simulation of maintenance treatment in first-line non-small cell lung cancer with external validation

por Han, Kelong, Claret, Laurent, Sandler, Alan, Das, Asha, Jin, Jin, Bruno, Rene
Publicado 2016

Lower Exposure and Faster Clearance of Bevacizumab in Gastric Cancer and the Impact of Patient Variables: Analysis of Individual Data from AVAGAST Phase III Trial

por Han, Kelong, Jin, Jin, Maia, Mauricio, Lowe, John, Sersch, Martina A., Allison, David E.
Publicado 2014

Comparison of Pharmacokinetics of the GalNAc-Conjugated Antisense Oligonucleotide GSK3389404 in Participants with Chronic Hepatitis B Infection across the Asia-Pacific Region

por Han, Kelong, Ito, Hiroshi, Elston, Robert, Cremer, Jennifer, Hood, Steve, Paff, Melanie, Theodore, Dickens
Publicado 2022

Progression-free survival as a surrogate endpoint for overall survival in glioblastoma: a literature-based meta-analysis from 91 trials

por Han, Kelong, Ren, Melanie, Wick, Wolfgang, Abrey, Lauren, Das, Asha, Jin, Jin, Reardon, David A.
Publicado 2014

Interpretation of meta-analysis evaluating progression-free survival as a surrogate endpoint for overall survival in glioblastoma

por Han, Kelong, Ren, Melanie, Wick, Wolfgang, Abrey, Lauren, Das, Asha, Jin, Jin, Reardon, David A.
Publicado 2015

1532. Population Pharmacokinetic (PPK) Modeling and Simulation of Long-Acting (LA) Cabotegravir (CAB) to Inform Strategies Following Dosing Interruptions in HIV-1-Infected Subjects

por Han, Kelong, Baker, Mark, Patel, Parul, Margolis, David, Spreen, William, Moore, Katy P, Ford, Susan L
Publicado 2019

Population pharmacokinetics of bevacizumab in cancer patients with external validation

por Han, Kelong, Peyret, Thomas, Marchand, Mathilde, Quartino, Angelica, Gosselin, Nathalie H., Girish, Sandhya, Allison, David E., Jin, Jin
Publicado 2016

Safety, Tolerability, Pharmacokinetics, and Acceptability of Oral and Long-Acting Cabotegravir in HIV-Negative Chinese Men

por Han, Kelong, Wannamaker, Paul, Lu, Hongzhou, Zhu, Biao, Wang, Meixia, Paff, Melanie, Spreen, William R., Ford, Susan L.
Publicado 2022

Preclinical and Phase 1 Assessment of Antisense Oligonucleotide Bepirovirsen in Hepatitis B Virus–Transgenic Mice and Healthy Human Volunteers: Support for Clinical Dose Selection...

por Han, Kelong, Theodore, Dickens, McMullen, Gina, Swayze, Eric, McCaleb, Michael, Billioud, Gaetan, Wieland, Stefan, Hood, Steve, Paff, Melanie, Bennett, C. Frank, Kwoh, T. Jesse
Publicado 2022

2495. Pharmacokinetics of Cabotegravir (CAB) and Rilpivirine (RPV) Long-Acting (LA) Injectables in HIV-infected Individuals through 48 Weeks in the FLAIR and ATLAS Phase 3 Studies

por Patel, Parul, Ford, Susan L, Crauwels, Herta, Han, Kelong, Rossenu, Stefaan, Neyens, Martine, Griffith, Sandy, Hudson, Krischan J, Margolis, David, Baker, Mark, Williams, Peter, Spreen, William
Publicado 2019

Bevacizumab dosing strategy in paediatric cancer patients based on population pharmacokinetic analysis with external validation

por Han, Kelong, Peyret, Thomas, Quartino, Angelica, Gosselin, Nathalie H., Gururangan, Sridharan, Casanova, Michela, Merks, Johannes H. M., Massimino, Maura, Grill, Jacques, Daw, Najat C., Navid, Fariba, Jin, Jin, Allison, David E.
Publicado 2015

Multicompartmental pharmacokinetic evaluation of long‐acting cabotegravir in healthy adults for HIV preexposure prophylaxis

por Shaik, Jafar Sadik, Weld, Ethel D., Edick, Stacey, Fuchs, Edward, Riddler, Sharon, Marzinke, Mark A., D'Amico, Ronald, Bakshi, Kalpana, Lou, Yu, Hendrix, Craig, Han, Kelong, Ford, Susan L., Margolis, David, Spreen, William, Patel, Parul
Publicado 2021

A Randomized, Double‐Blind, Placebo‐Controlled, First‐Time‐in‐Human Study to Assess the Safety, Tolerability, and Pharmacokinetics of Single and Multiple Ascending Doses of GSK3389...

por Han, Kelong, Cremer, Jennifer, Elston, Robert, Oliver, Stuart, Baptiste‐Brown, Sharon, Chen, Shuguang, Gardiner, David, Davies, Matt, Saunders, Joanne, Hamatake, Robert, Losos, Jan, Leivers, Martin, Hood, Steve, van der Berg, Frans, Paff, Melanie, Ritter, James M., Theodore, Dickens
Publicado 2019

Population pharmacokinetics of cabotegravir following administration of oral tablet and long‐acting intramuscular injection in adult HIV‐1‐infected and uninfected subjects

por Han, Kelong, Baker, Mark, Lovern, Mark, Paul, Prokash, Xiong, Yuan, Patel, Parul, Moore, Katy P., Seal, Ciara S., Cutrell, Amy G., D'Amico, Ronald D., Benn, Paul D., Landovitz, Raphael J., Marzinke, Mark A., Spreen, William R., Ford, Susan L.
Publicado 2022

Multiparametric magnetic resonance imaging to characterize cabotegravir long‐acting formulation depot kinetics in healthy adult volunteers

por Jucker, Beat M., Fuchs, Edward J., Lee, Sarah, Damian, Valeriu, Galette, Paul, Janiczek, Robert, Macura, Katarzyna J., Jacobs, Michael A., Weld, Ethel D., Solaiyappan, Meiyappan, D'Amico, Ronald, Shaik, Jafar Sadik, Bakshi, Kalpana, Han, Kelong, Ford, Susan, Margolis, David, Spreen, William, Gupta, Manish K., Hendrix, Craig W., Patel, Parul
Publicado 2021

Expanded Multivariable Models to Assist Patient Selection for Long-Acting Cabotegravir + Rilpivirine Treatment: Clinical Utility of a Combination of Patient, Drug Concentration, an...

por Orkin, Chloe, Schapiro, Jonathan M, Perno, Carlo F, Kuritzkes, Daniel R, Patel, Parul, DeMoor, Rebecca, Dorey, David, Wang, Yongwei, Han, Kelong, Van Eygen, Veerle, Crauwels, Herta, Ford, Susan L, Latham, Christine L, St. Clair, Marty, Polli, Joseph W, Vanveggel, Simon, Vandermeulen, Kati, D’Amico, Ronald, Garges, Harmony P, Zolopa, Andrew, Spreen, William R, van Wyk, Jean, Cutrell, Amy G
Publicado 2023